EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.
You may also be interested in...
The European Medicines Agency has announced the post-authorization procedures that the newly reassigned (co-)rapporteurs must start handling as of this month.
The EMA is halting its cherished transparency initiative on study data as it reckons with the fact that many of its employees will not be relocating to its new headquarters in Amsterdam. International collaboration, guidelines development and revision, and the agency's involvement in stakeholder meetings will all be cut back.
The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.